Clinical Trial

A Study to Investigate Efficacy, Safety, Tolerability, and Pharmacokinetics of JZP441 Compared With Placebo in Participants With Narcolepsy Type 1

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
The study was terminated based on a business decision by the Sponsor.
Summary
Narcolepsy is a sleep disorder in which patients are not able to maintain wakefulness or require treatment to maintain wakefulness during the daytime. Narcolepsy is a lifelong neurologic disease for which no cure has been clinically available. JZP441 is currently being developed for the treatment of narcolepsy type 1 (NT1). This study will assess the safety of efficacy of JZP441 in adult patients with NT1.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-04-29; most recent amendment 2026-03-31.
Status change: Recruiting → Terminated 2026-03-31
Status change: Not Yet Recruiting → Recruiting 2025-05-14
Trial Details
NCT Number NCT06961266
Lead Sponsor Jazz Pharmaceuticals
Collaborators: Jazz Pharmaceuticals Ireland Limited
Conditions Narcolepsy
Enrollment 6 participants
Start Date 2025-05-13
Primary Completion 2026-01-29 (estimated)
Study Completion 2026-01-29 (estimated)
Updated on ClinicalTrials.gov 2026-04-06